TY - JOUR
T1 - Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?
AU - Isfordink, Cas J.
AU - Maan, Raoel
AU - de Man, Robert A.
AU - van Erpecum, Karel J.
AU - van der Meer, Adriaan J.
N1 - Funding Information:
Cas J Isfordink follows a PhD traject in the CELINE (hepatitis C elimination in the Netherlands) initiative sponsored by Gilead. Raoel Maan received financial compensation for consultancy from AbbVie. Robert A de Man has nothing to disclose. Karel J van Erpecum participated in advisory boards of Gilead, Janssen-Cilag, BMS, Abbvie, and MSD and received research grants from Gilead, Janssen-Cilag and the DutchCancer Society (KWF Kankerbestrijding). Adriaan J van der Meer received financial compensation for lecture activities from Zambon, research funding from Gilead, MSD, AbbVie and Zambon, and compensation for consultancy from AOP Orphan.
Publisher Copyright:
© 2021
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Hepatocellular carcinoma (HCC) and variceal bleeding are among the most common causes of liver-related mortality in patients with hepatitis C virus (HCV)-induced cirrhosis. Current guidelines recommend HCC and gastroesophageal varices (GEV) surveillance in patients with HCV infection and cirrhosis. However, since the recent introduction of direct-acting antivirals, most patients with cirrhosis are now cured of their chronic HCV infection. As virological cure is considered to substantially reduce the risk of cirrhosis-related complications, this review discusses the current literature concerning the surveillance of HCC and GEV in patients with HCV-induced cirrhosis with a focus on the setting following sustained virological response.
AB - Hepatocellular carcinoma (HCC) and variceal bleeding are among the most common causes of liver-related mortality in patients with hepatitis C virus (HCV)-induced cirrhosis. Current guidelines recommend HCC and gastroesophageal varices (GEV) surveillance in patients with HCV infection and cirrhosis. However, since the recent introduction of direct-acting antivirals, most patients with cirrhosis are now cured of their chronic HCV infection. As virological cure is considered to substantially reduce the risk of cirrhosis-related complications, this review discusses the current literature concerning the surveillance of HCC and GEV in patients with HCV-induced cirrhosis with a focus on the setting following sustained virological response.
UR - http://www.scopus.com/inward/record.url?scp=85115626402&partnerID=8YFLogxK
U2 - 10.1016/j.ejim.2021.08.023
DO - 10.1016/j.ejim.2021.08.023
M3 - Review article
C2 - 34563447
AN - SCOPUS:85115626402
VL - 94
SP - 6
EP - 14
JO - European Journal of Internal Medicine
JF - European Journal of Internal Medicine
SN - 0953-6205
ER -
